Table 2.

Univariable and multivariable analyses of prognostic impact (5-year overall survival) of clinicopathological and molecular variables

		Univariable analysis		Multivariable analysisa
Variable	Patients, n (%)	HR (95% CI)	P	HR (95% CI)	P
Total	1197 (100)
Gender
Male	563 (47)	1		1
Female	634 (53)	1.03 (0.87–1.23)	0.713	0.91 (0.75–1.11)	0.362
Age
≤70	493 (41)	1		1
>70	704 (59)	1.57 (1.31–1.89)	<0.001	2.00 (1.63–2.44)	<0.001
MSI status
MSS	993 (84)	1		1
MSI	184 (16)	0.66 (0.50–0.86)	0.002	0.52 (0.36–0.77)	0.001
Location
Right	493 (41)	1		1
Left	369 (31)	1.06 (0.87–1.29)	0.574	1.02 (0.81–1.29)	0.877
Rectum	312 (26)	0.82 (0.66–1.02)	0.078	0.96 (0.74–1.25)	0.751
Stage
I	195 (16)	1		1
II	475 (40)	1.49 (1.07–2.08)		1.37 (0.95–1.99)
III	327 (27)	2.54 (1.82–3.54)		2.52 (1.75–3.63)
IV	198 (17)	10.17 (7.30–14.16)	<0.001	10.34 (7.18–14.90)	<0.001
Differentiation
High	72 (6)	1		1
Medium	932 (80)	0.97 (0.68–1.40)		1.07 (0.70–1.62)
Lowb	164 (14)	1.66 (1.11–2.47)	<0.001	1.87 (1.17–3.0)	<0.001
KRAS and/or BRAFc
Both wt	570 (52)	1		1
KRAS mut	339 (31)	1.28 (1.05–1.56)	0.016	1.21 (0.98–1.49)	0.08
BRAF mut	192 (17)	1.29 (1.01–1.64)	0.043	1.61 (1.15–2.23)	0.005

See supplementary Table S3, available at Annals of Oncology online, for analyses of relapse-free survival.

^aIncludes all variables in the table. n = 1037, 160 cases dropped due to missing variables.

^bIncludes mucinous.

^cIncludes only patients with conclusive wild type status in both genes or conclusive mutation in one gene.

mut, mutation; wt, wild-type. Statistically significant P values in bold.